V591 SARS-CoV-2 Vaccine Description
Merck's V591 SARS-CoV-2 Vaccine candidate uses a measles virus vector platform to deliver the antigens to the immune system to spur antibody production against the SARS-CoV-2 virus.
Merck's Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications.
In March 2020, Themis joined a consortium together with the Institut Pasteur and The Center for Vaccine Research at the University of Pittsburgh, supported by funding from the Coalition for Epidemic Preparedness Innovations, to develop a vaccine candidate targeting SARS-CoV-2 for the prevention of COVID-19.
For more information, visit www.merck.com.
V591 SARS-CoV-2 Vaccine Indication
V591 SARS-CoV-2 Vaccine is indicated to prevent COVID-19 disease which is caused by the SARS-CoV-2 coronavirus.
V591 SARS-CoV-2 Vaccine News
October 27, 2020 - Merck published COVID-19 Research Highlights.
June 19, 2020 - Milestone Reflects Merck’s Commitment to Accelerate SARS-CoV-2 Vaccine Program.
May 26, 2020 - Merck and Themis announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis.
V591 SARS-CoV-2 Vaccine Clinical Trial
Clinical Trial NCT04498247: A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001). Last Update Posted: October 22, 2020.
- The primary objective of this early Phase 1 study is to identify the V591 dose that achieves the target immune response in humans based on preclinical or early clinical data.
- Participants in the 18 to 55-year-old sentinel cohort will receive 1 or 2 doses (Day 1 and Day 57) of V591 or placebo.